An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
StatPearls [Internet].
Treasure Island (FL): StatPearls Publishing; 2025 Jan-.
Top results in this bookTable of Contents
Webvision: The Organization of the Retina and Visual System [Internet].
Kolb H, Fernandez E, Jones B, et al., editors.
Salt Lake City (UT): University of Utah Health Sciences Center; 1995-.
Madame Curie Bioscience Database [Internet].
Austin (TX): Landes Bioscience; 2000-2013.
Endotext [Internet].
Feingold KR, Adler RA, Ahmed SF, et al., editors.
South Dartmouth (MA): MDText.com, Inc.; 2000-.
GeneReviews® [Internet].
Adam MP, Bick S, Mirzaa GM, et al., editors.
Seattle (WA): University of Washington, Seattle; 1993-2026.
Jasper's Basic Mechanisms of the Epilepsies. 5th edition.
Noebels JL, Avoli M, Rogawski MA, et al., editors.
New York: Oxford University Press; 2024.
Clinical Review Report: Dexamethasone (Ozurdex): (Allergan Inc.): Indication: For the treatment of adult patients with diabetic macular edema who are pseudophakic [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Nov.
Advancing Gene-Targeted Therapies for Central Nervous System Disorders: Proceedings of a Workshop.
National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Forum on Neuroscience and Nervous System Disorders; Stroud C, Bain L, editors.
Washington (DC): National Academies Press (US); 2019 Sep 20.
High Resolution Imaging in Microscopy and Ophthalmology: New Frontiers in Biomedical Optics [Internet].
Bille JF, editor.
Cham (CH): Springer; 2019.
Alzheimer’s Disease [Internet].
Wisniewski T, editor.
Brisbane (AU): Codon Publications; 2019 Dec 20.
Age-related macular degeneration: diagnosis and management.
London: National Institute for Health and Care Excellence (NICE); 2018 Jan. (NICE Guideline, No. 82.)
A randomised controlled trial of adjunctive triamcinolone acetonide in eyes undergoing vitreoretinal surgery for open globe trauma – the ASCOT study.
Charteris DG, Cro S, Casswell E, et al.
Southampton (UK): National Institute for Health and Care Research; 2023 Jul. (Health Technology Assessment, No. 27.12.)
Gene therapy for choroideremia using an adeno-associated viral vector encoding Rab escort protein 1: the REGENERATE open-label trial.
Cehajic-Kapetanovic J, Bellini MP, Taylor LJ, et al.; REGENERATE Study Group.
Southampton (UK): National Institute for Health and Care Research; 2024 May. (Efficacy and Mechanism Evaluation, No. 11.09.)
Basic Neurochemistry: Molecular, Cellular and Medical Aspects. 6th edition.
Siegel GJ, Agranoff BW, Albers RW, et al., editors.
Philadelphia: Lippincott-Raven; 1999.
Faricimab (Vabysmo): Therapeutic area: Retinal vein occlusion: Reimbursement Review [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2025 Jun.
Regulation of Endothelial Barrier Function.
Yuan SY, Rigor RR.
San Rafael (CA): Morgan & Claypool Life Sciences; 2010.
Holland-Frei Cancer Medicine. 6th edition.
Kufe DW, Pollock RE, Weichselbaum RR, et al., editors.
Hamilton (ON): BC Decker; 2003.
Inorganic and Organic Lead Compounds.
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans.
Lyon (FR): International Agency for Research on Cancer; 2006. (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, No. 87.)
Faricimab (Vabysmo): Indication: For the treatment of macular edema secondary to retinal vein occlusion: Reimbursement Recommendation [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2025 Mar.
Clinical Review Report: Levodopa/Carbidopa (Duodopa): (Abbvie Corporation): Indication: For the treatment of patients with advanced levodopa-responsive Parkinson’s disease who do not have satisfactory control of severe, debilitating motor fluctuations and hyper-/dyskinesia despite optimized treatment with available combinations of Parkinson’s medicinal products, and, for whom the benefits of this treatment may outweigh the risks associated with the insertion and long-term use of the percutaneous endoscopic gastrostomy-jejunostomy (PEG-J) tube required for administration [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Sep.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on